A phase Ib, placebo-controlled randomized clinical trial of the Ebolavirus DNA vaccine candidate INO-4201 followed by electroporation as booster vaccination in healthy, rVSVΔG-ZEBOV-GP-primed volunteers (Boost-EBOV)

Angela Huttner; Marc-Antoine de La Vega; Cristina Boehm-Bosmani; Jean Boyer; Christiane Eberhardt; Paola Fontannaz; Elisabeth Gillespie; Sylvain Lemeille; Matthew P. Morrow; Marie-Edith Nepveu-Traversy; Bonaventure Orizu; Emma L. Reuschel; Romain Roth; Hiba Sharkhith; Albert J. Sylvester; Pauline Vetter; Laurent M. Humeau; Judith Pignac-Kobinger; Dave Liebowitz; Arnaud M. Didierlaurent; Claire-Anne Siegrist; Gary P. Kobinger

doi:10.1016/j.cmi.2026.01.019

A phase Ib, placebo-controlled randomized clinical trial of the Ebolavirus DNA vaccine candidate INO-4201 followed by electroporation as booster vaccination in healthy, rVSVΔG-ZEBOV-GP-primed volunteers (Boost-EBOV)

Clinical Microbiology and Infection 2026

View at publisher

Authors: Angela Huttner, Marc-Antoine de La Vega, Cristina Boehm-Bosmani, Jean Boyer, Christiane Eberhardt, Paola Fontannaz, Elisabeth Gillespie, Sylvain Lemeille, Matthew P. Morrow, Marie-Edith Nepveu-Traversy, Bonaventure Orizu, Emma L. Reuschel

+10 more

Romain Roth, Hiba Sharkhith, Albert J. Sylvester, Pauline Vetter, Laurent M. Humeau, Judith Pignac-Kobinger, Dave Liebowitz, Arnaud M. Didierlaurent, Claire-Anne Siegrist, Gary P. Kobinger

DOI: 10.1016/j.cmi.2026.01.019

Cited by: 2

References: 26

Fields of Study & Subjects

Viral Infections and Outbreaks Research Bacillus and Francisella bacterial research SARS-CoV-2 and COVID-19 Research

Publication details

Journal / source: Clinical Microbiology and Infection
Publisher: Elsevier BV
Volume: 32
Issue: 7
Pages: 1158–1164
Publication date: 27 January 2026
Language: EN

References 26